摘要
目的:探究头孢西丁钠联合康妇消炎栓于盆腔炎规范化治疗中应用的疗效。方法:选取2023年2月至2023年10月民勤县社区卫生服务中心妇产科收治的80例盆腔炎患者作为研究对象,按随机平均分组分为对照组与实验组,每组40例。实验组接受头孢西丁钠联合康妇消炎栓治疗,对照组仅接受头孢西丁钠治疗。对比两组患者诊疗前后的炎症情况、不良反应发生率。结果:治疗后,两组患者的肿瘤坏死因子(TNF-α)、C反应蛋白(CRP)水平及炎性包块直径、盆腔积液深度均降低,且实验组显著低于对照组(P<0.05);两组患者的白细胞介素-2(IL-2)均增高,且实验组显著高于对照组(P<0.05);对照组患者的不良反应发生率稍高于实验组(P>0.05)。结论:头孢西丁钠联合康妇消炎栓应用于盆腔炎患者的规范化治疗中具有显著作用,可改善炎症反应,缓解其临床症状。
Objective:To explore the efficacy of cefoxitin sodium combined with kangfu anti-inflammatory suppository in the standardized treatment of pelvic inflammatory disease.Methods:A total of 80 patients with pelvic inflammatory disease admitted to the Obstetrics and Gynecology Department of Minqin County Community Health Service Center from February 2023 to October 2023 were selected as the research objects and divided into the control group and the experimental group according to random average grouping,with 40 cases in each group.The experimental group received cefoxitin sodium combined with kangfu anti-inflammatory suppository treatment,and the control group received only cefoxitin sodium treatment.The inflammation and incidence of adverse reactions before and after diagnosis and treatment were compared between the two groups.Results:After treatment,the levels of tumor necrosis factor(TNF-α)and C-reactive protein(CRP),the diameter of inflammatory mass and the depth of pelvic fluid in the two groups were decreased,and the experimental group was significantly lower than the control group(P<0.05).Interleukin-2(IL-2)was increased in both groups,and the experimental group was significantly higher than the control group(P<0.05).The incidence of adverse reactions in the control group was slightly higher than that in the experimental group(P>0.05).Conclusion:Cefoxitin sodium combined with kangfu anti-inflammatory suppository has a significant effect in the standardized treatment of patients with pelvic inflammatory disease,which can improve the inflammatory response and relieve the clinical symptoms.
作者
王春霞
WANG Chun-xia(Minqin County Community Health Service Center)
出处
《中国标准化》
2024年第4期289-292,共4页
China Standardization
关键词
康妇消炎栓
头孢西丁钠
盆腔炎
kangfu anti-inflammatory suppository
cefoxitin sodium
pelvic inflammatory disease
